Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. reduced its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 1.3% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 489,199 shares of the company’s stock after selling 6,611 shares during the quarter. JPMorgan Chase & Co. owned about 0.69% of Zentalis Pharmaceuticals worth $1,800,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of the company. GSA Capital Partners LLP grew its stake in Zentalis Pharmaceuticals by 138.5% in the 3rd quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock valued at $2,240,000 after acquiring an additional 353,384 shares during the last quarter. Decheng Capital LLC grew its stake in Zentalis Pharmaceuticals by 46.2% in the 2nd quarter. Decheng Capital LLC now owns 3,070,442 shares of the company’s stock valued at $12,558,000 after acquiring an additional 970,859 shares during the last quarter. Verition Fund Management LLC grew its stake in Zentalis Pharmaceuticals by 172.1% in the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock valued at $5,536,000 after acquiring an additional 951,500 shares during the last quarter. Barclays PLC grew its stake in Zentalis Pharmaceuticals by 18.5% in the 3rd quarter. Barclays PLC now owns 75,395 shares of the company’s stock valued at $277,000 after acquiring an additional 11,748 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in Zentalis Pharmaceuticals by 152.6% in the 2nd quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock valued at $2,706,000 after acquiring an additional 399,745 shares during the last quarter.

Zentalis Pharmaceuticals Stock Performance

ZNTL opened at $2.26 on Thursday. The firm has a 50 day moving average price of $3.11 and a 200 day moving average price of $3.36. The company has a market cap of $161.06 million, a PE ratio of -0.91 and a beta of 1.86. Zentalis Pharmaceuticals, Inc. has a 1 year low of $2.16 and a 1 year high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36. On average, sell-side analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ZNTL. Guggenheim reduced their target price on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, November 15th. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, November 15th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $10.00.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.